R
Richard B. Womer
Researcher at Children's Hospital of Philadelphia
Publications - 131
Citations - 8762
Richard B. Womer is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Sarcoma & Rhabdomyosarcoma. The author has an hindex of 44, co-authored 127 publications receiving 7744 citations. Previous affiliations of Richard B. Womer include Boston Children's Hospital & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,Eugenie S. Kleinerman,Donna L. Betcher,Mark L. Bernstein,Ernest U. Conrad,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,John H. Healey,Andrew G. Huvos,Michael P. Link,Joseph Montebello,Helen Nadel,Michael Nieder,Judith K. Sato,Gene P. Siegal,Michael Weiner,Robert J. Wells,Lester E. Wold,Richard B. Womer,Holcombe E. Grier +23 more
TL;DR: The addition of MTP to chemotherapy might improve EFS, but additional clinical and laboratory investigation will be necessary to explain the interaction between ifosfamide and MTP.
Journal ArticleDOI
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,John H. Healey,Mark L. Bernstein,Donna L. Betcher,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,Eugenie S. Kleinerman,Michael P. Link,Helen Nadel,Michael Nieder,Gene P. Siegal,Michael A. Weiner,Robert J. Wells,Richard B. Womer,Holcombe E. Grier +18 more
TL;DR: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma, and the addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.
Journal ArticleDOI
Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Richard B. Womer,Daniel C. West,Mark Krailo,Paul S. Dickman,Bruce R. Pawel,Holcombe E. Grier,Karen J. Marcus,Scott L. Sailer,John H. Healey,John P. Dormans,Aaron R. Weiss +10 more
TL;DR: For localized Ewing sarcoma, chemotherapyadministered every 2 weeks is more effective than chemotherapy administered every 3 weeks, with no increase in toxicity.
Journal ArticleDOI
Ewing's sarcoma
TL;DR: The EWS-ETS family of gene fusions and their downstream effects in Ewing's sarcomas provide opportunities for new approaches to treatment, including the inhibition of the fusion gene or its protein product, and pathways related to IGF1 and mTOR.
Journal ArticleDOI
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
E de Alava,Akira Kawai,John H. Healey,I. Fligman,P. A. Meyers,Andrew G. Huvos,William L. Gerald,Suresh C. Jhanwar,Pedram Argani,C. R. Antonescu,F J Pardo-Mindán,Jill P. Ginsberg,Richard B. Womer,Elizabeth R. Lawlor,Jay S. Wunder,Irene L. Andrulis,Poul H. Sorensen,Frederic G. Barr,Marc Ladanyi +18 more
TL;DR: EWS-FLI1 fusion type appears to be prognostically relevant in ES, independent of tumor site, stage, and size.